JP2021526833A5 - - Google Patents

Info

Publication number
JP2021526833A5
JP2021526833A5 JP2020569130A JP2020569130A JP2021526833A5 JP 2021526833 A5 JP2021526833 A5 JP 2021526833A5 JP 2020569130 A JP2020569130 A JP 2020569130A JP 2020569130 A JP2020569130 A JP 2020569130A JP 2021526833 A5 JP2021526833 A5 JP 2021526833A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
elabela
antibody
Prior art date
Application number
JP2020569130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021526833A (ja
JPWO2019238093A5 (https=
JP7674837B2 (ja
Filing date
Publication date
Priority claimed from CN201810606914.0A external-priority patent/CN110655577A/zh
Application filed filed Critical
Publication of JP2021526833A publication Critical patent/JP2021526833A/ja
Publication of JPWO2019238093A5 publication Critical patent/JPWO2019238093A5/ja
Publication of JP2021526833A5 publication Critical patent/JP2021526833A5/ja
Application granted granted Critical
Publication of JP7674837B2 publication Critical patent/JP7674837B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020569130A 2018-06-13 2019-06-13 Apj抗体及びelabelaとのその融合タンパク質並びにその医薬組成物及び用途 Active JP7674837B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810606914.0 2018-06-13
CN201810606914.0A CN110655577A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用
PCT/CN2019/091090 WO2019238093A1 (zh) 2018-06-13 2019-06-13 APJ抗体及其与Elabela的融合蛋白质,以及其药物组合物和应用

Publications (4)

Publication Number Publication Date
JP2021526833A JP2021526833A (ja) 2021-10-11
JPWO2019238093A5 JPWO2019238093A5 (https=) 2022-06-22
JP2021526833A5 true JP2021526833A5 (https=) 2022-06-22
JP7674837B2 JP7674837B2 (ja) 2025-05-12

Family

ID=68842717

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020569130A Active JP7674837B2 (ja) 2018-06-13 2019-06-13 Apj抗体及びelabelaとのその融合タンパク質並びにその医薬組成物及び用途

Country Status (8)

Country Link
US (1) US12221488B2 (https=)
EP (1) EP3808847A4 (https=)
JP (1) JP7674837B2 (https=)
KR (1) KR102880176B1 (https=)
CN (2) CN119613548A (https=)
AU (1) AU2019284320B2 (https=)
CA (1) CA3103585A1 (https=)
WO (1) WO2019238093A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210001A (zh) * 2020-10-25 2021-01-12 兰州大学 多肽片段ela13及其用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
ATE240394T1 (de) 1992-10-23 2003-05-15 Immunex Corp Methoden zur herstellung löslicher, oligomerer proteine
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
AU1685499A (en) 1997-12-24 1999-07-19 Takeda Chemical Industries Ltd. Polypeptide, their production and use
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
DE10138569A1 (de) * 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2005106493A1 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
US20060045880A1 (en) 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2012102363A1 (ja) 2011-01-28 2012-08-02 国立大学法人大阪大学 薬物送達システムおよびその利用
US9156911B2 (en) * 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
BR112014003315A2 (pt) * 2011-08-15 2017-03-01 Univ Chicago composições e métodos relacionados a anticorpos para a proteína a estafilocócica
WO2014152955A1 (en) * 2013-03-14 2014-09-25 Regeneron Pharmaceuticals, Inc. Apelin fusion proteins and uses thereof
CN104371019B (zh) * 2013-08-13 2019-09-10 鸿运华宁(杭州)生物医药有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN105916881A (zh) * 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
WO2015140296A2 (en) 2014-03-20 2015-09-24 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
CN106659774A (zh) * 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
ES2854400T3 (es) 2014-10-13 2021-09-21 Univ Maryland Fc-ELA--32 y su uso en el tratamiento de afecciones cardiacas
US10273305B2 (en) * 2015-04-02 2019-04-30 Ablynx N.V. Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
AU2018322452A1 (en) * 2017-08-24 2020-03-05 Phanes Therapeutics, Inc. Anti-apelin antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2020180158A5 (https=)
JP2024150751A5 (https=)
JP2019520797A5 (https=)
JP6669722B2 (ja) Cd3結合ドメイン
RU2018142544A (ru) Биспецифические связывающие белки и пути их применения
JP2020508655A5 (https=)
JP2021503455A5 (https=)
RU2016108703A (ru) Антитело, специфически связывающееся с glp-1r, и его слитый с glp-1 белок
JP2019116474A5 (https=)
US20220340677A1 (en) Split intein and preparation method for recombinant polypeptide using the same
NZ717476A (en) Anti-garp protein and uses thereof
JP2018522888A5 (https=)
JP2020536532A5 (https=)
JP2017504578A5 (https=)
JP2017514515A5 (https=)
JP2021518132A5 (https=)
JPWO2019129221A5 (https=)
JP2019502694A5 (https=)
JP2020524661A5 (https=)
JP2013523184A5 (https=)
JP2018510617A5 (https=)
US20240209082A1 (en) Anti-cd96 antibodies and methods of use thereof
JP2011526249A5 (https=)
JP2019504617A5 (https=)
JP2021511387A5 (https=)